Investigators at the Dana Farber Cancer Institute (DFCI) reported the outcomes of 1490 patients with metastatic NSCLC whose tumors were genetically profiled by targeted NGS focusing on the six BAF genes most often altered in NSCLC (SMARCA4, ARID1A, ARID1B, ARID2, PBRM1, and SMARCB1) [16]. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.